

# Clinical Monitoring of Patients Receiving Repeated Intravitreal Pharmacotherapy: A Multidisciplinary Approach

Haziel Rynjah<sup>1</sup>, Ayush Wilson<sup>2</sup>, Ankita Konwar<sup>3</sup>, Sourabh De<sup>4</sup>, Replantful Chiangkata<sup>5</sup>,  
Mrityunjoy Bose<sup>6</sup>

<sup>1</sup>Assistant Professor, Department of Optometry, Royal Global University, Assam, India

<sup>2</sup>Assistant Professor, Department of Optometry, Sushant University, Gurgaon, India

<sup>3</sup>M.OPTOM Student, Department of Optometry, Royal Global University, Assam, India

<sup>4</sup>Assistant Professor, Department of Optometry, Chandigarh School of Business (CGC) University, Punjab, India

<sup>5</sup>Assistant Professor, Department of Pharmacy, University of Science and Technology Meghalaya (USTM), Meghalaya, India

<sup>6</sup>PhD Scholar, Department of Optometry, Assam Down Town University

## ABSTRACT

**Background:** For several retinal illnesses, such as neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, the conventional treatment is repeated intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF), e.g., Ranibizumab, Aflibercept, Bevacizumab medicines and corticosteroids. Patients frequently need long-term injections, so it's important to monitor them closely to see how they are responding to treatment, identify any problems, and prevent their vision from worsening.

**Objective:** Optometrists are very important in the co-management of these patients since they do full visual and ocular exams between injection appointments. This review discusses optometric evaluation protocols, structural and functional monitoring strategies, complications associated with repeated intravitreal therapy, and the role of optometrists in optimizing patient outcomes.

**Keywords:** Corticosteroid, intravitreal, anti-VEGF therapy, optometric monitoring, retinal diseases

**How to cite this article:** Rynjah H, Wilson A, Konwar A, De S, Chiangkata R, Bose M. Clinical Monitoring of Patients Receiving Repeated Intravitreal Pharmacotherapy: A Multidisciplinary Approach. *Int J Drug Deliv Technol.* 2026;16(13s): 546-548. DOI: 10.25258/ijddt.16.13s.60

**Source of support:** Nil.

**Conflict of interest:** None

## Introduction

Intravitreal medication has revolutionized the treatment of retinal illnesses that formerly resulted in permanent vision loss. The introduction of anti-VEGF agents and sustained-release corticosteroid implants has significantly improved visual prognosis [1]. But these treatments have to be given again and again over months or years, which puts patients at danger of getting more eye problems and having to deal with the treatment [2].

Optometrists often see patients who are getting intravitreal treatment in basic eye care settings. They are responsible for keeping an eye on visual acuity, retinal status, intraocular pressure, ocular surface health, and finding side effects early on. Good optometric monitoring helps people get to retina specialists on time and leads to the best possible vision outcomes [3].

## Reasons for Repeated Intravitreal Injections

Repeated intravitreal injections are often necessary for:

- Diabetic macular edema.

- Neovascular (wet) age-related macular degeneration.
  - Retinal vein occlusion (branch and central).
  - Myopic choroidal neovascularization.
  - Uveitic macular edema (steroid therapy).
- These disorders frequently necessitate personalized treatment regimens, including monthly dosage, treat-and-extend protocols, or on-demand injections [4].

## Protocol for Optometric Evaluation

Evaluating visual function is essential for assessing therapy efficacy. Important parts are:

- Best-corrected visual acuity for distance and near [5].
- Contrast sensitivity testing.
- Amsler grid evaluation for metamorphopsia [5].
- Assessment of reading performance and quality of vision.

Changes in how well you can see may mean that the condition is becoming worse, that the treatment isn't working, or that there are problems.

## Evaluation of the Retina's Structure

## Clinical Monitoring of Patients Receiving Repeated Intravitreal Pharmacotherapy: A Multidisciplinary Approach

- Optical coherence tomography (OCT) to evaluate macular thickness, fluid accumulation, and retinal architecture [6].
- Fundus examination to identify hemorrhages, exudates, or fibrosis [5,6].
- Documentation through fundus photography when available [6].
- Optometrists who know how to read OCT can tell if edema or subretinal fluid is coming back and needs to be treated again [6].

### Techniques for Monitoring Images

Advanced retinal imaging techniques help doctors keep an eye on how diseases are getting worse and how well treatments are working.

- FFA stands for Fundus Fluorescein Angiography.
  - FFA is useful for checking for retinal vascular leakage, ischaemia, and neovascularisation [6].
- OCT (Optical Coherence Tomography).
  - OCT is a way to take pictures of the retina and choroidal vasculature without using dye [6,7].

### Monitoring of the Anterior Segment and Intraocular Pressure

- Measurement of intraocular pressure at each visit [6].
- Repeated intravitreal injections can have an impact on the health of the anterior segment [6].
- Slit-lamp examination for inflammation, infection, or corneal changes [5,6].
- Assessment of ocular surface disease and dry eye [6].
- Monitoring for cataract progression, particularly with corticosteroid therapy [6].
- Transient or persistent increases in intraocular pressure are recognized complications necessitating prompt intervention [5,6].
- Central visual field [6].
- Color vision testing [6].
  - Patient-reported outcome measures [6].

Table 1: Clinical Monitoring Parameters in Patients Receiving Repeated Intravitreal Therapy

Monitoring Parameter	Clinical Purpose
Visual acuity	To evaluate the patient's level of vision and monitor improvement or deterioration after treatment
Optical Coherence Tomography (OCT)	To assess macular thickness and detect retinal fluid or macular edema
Intraocular pressure (IOP)	To measure fluid pressure inside the eye and detect steroid-induced ocular hypertension or glaucoma

Monitoring Parameter	Clinical Purpose
Fundus examination	To observe retinal structures and detect hemorrhage, exudates, or fibrosis
Amsler grid test	To detect central visual distortion (metamorphopsia) and early macular changes

### Complications Associated with Repeated Intravitreal Injections

#### Ocular Complications

Ocular complications include

- Endophthalmitis.
- Retinal detachment.
- Vitreous hemorrhage.
- Sustained ocular hypertension or glaucoma [9].
- Cataract formation.

Early recognition of warning signs such as pain, redness, photophobia, or sudden vision loss is critical for urgent referral [8].

#### Functional and Quality-of-Life Issues

Patients receiving long-term therapy may experience:

- Fluctuating vision between injections.
  - Persistent distortion or scotomas.
  - Reduced contrast sensitivity.
  - Treatment fatigue and compliance challenges.
- Optometrists can provide counseling and visual rehabilitation strategies [9].

#### Education and Follow-up for Patients

Teaching patients is an important part of keeping them from having problems [9,10].

Patients should know about symptoms that need immediate medical care, such as:

- Very bad eye pain.
  - Vision loss all of a sudden.
  - Getting redder.
  - Fear of light.
  - Floaters that have just started.
- Reporting these symptoms right away makes it possible to act quickly and lowers the chance of serious complications [10].

#### Role of Optometrists in Co-Management

Optometrists serve as primary eye care providers who bridge the gap between injection visits [11]. Their responsibilities include:

- Routine monitoring of visual and ocular status [12].
- Patient education regarding symptoms of complications.
- Reinforcing adherence to follow-up schedules.

## Clinical Monitoring of Patients Receiving Repeated Intravitreal Pharmacotherapy: A Multidisciplinary Approach

- Communicating findings to retina specialists.
- Managing coexisting ocular conditions such as dry eye or refractive errors [13].

This collaborative approach enhances patient safety and treatment success.

### Future Perspectives

Improvements in retinal imaging, home monitoring devices, and long-acting drug delivery systems are likely to make therapy less of a burden and lead to better results. Optometrists will still be very important in making sure these new ideas are used in clinical practice [14].

### Conclusion

In current retinal therapy, repeated intravitreal injections are very important, but they need to be watched closely to make sure they are safe and work. A thorough optometric examination of visual function, retinal structure, intraocular pressure, and ocular health is crucial for the early identification of difficulties and the enhancement of visual outcomes [15]. To provide high-quality, patient-centered care, it is important to improve cooperation between optometrists and retina specialists.

### Reference

1. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. *Retina*. 2009 Jul 1;29(7):875-912.
2. Jager RD, Aiello LP, Patel SC, Cunningham Jr ET. Risks of intravitreal injection: a comprehensive review. *Retina*. 2004 Oct 1;24(5):676-98
3. Hanson C, Tennant MT, Rudnisky CJ. Optometric referrals to retina specialists: evaluation and triage via teleophthalmology. *TELEMEDICINE and e-HEALTH*. 2008 Jun;14(5):441-5.
4. Eleftheriadou M, Nicholson L, D'Alonzo G, Addison PK. Real-life evidence for using a treat-and-extend injection regime for patients with central retinal vein occlusion. *Ophthalmology and Therapy*. 2019 Jun;8(2):289-96.
5. Simunovic MP. Metamorphopsia and its quantification. *Retina*. 2015 Jul 1;35(7):1285-91.
6. Meyer CH, Melo GB, Khanani AM. Can intravitreal injections with higher volume cause higher intraocular eye pressure? Considerations for anti-complement injections in normal and glaucomatous eyes. *International Journal of Retina and Vitreous*. 2023 Dec 14;9(1):80.
7. Borrelli E, Sarraf D, Freund KB, Sadda SR. OCT angiography and evaluation of the choroid and choroidal vascular disorders. *Progress in retinal and eye research*. 2018 Nov 1;67:30-55.
8. Kilduff C, Lois C. Red eyes and red-flags: improving ophthalmic assessment and referral in primary care. *BMJ Quality Improvement Reports*. 2016 Jun 28;5(1).
9. Barr W, Hodge S, Leeven M, Bowen L, Knox P. Emotional support and counselling for people with visual impairment: Quantitative findings from a mixed methods pilot study. *Counselling and Psychotherapy Research*. 2012 Dec 1;12(4):294-302.
10. Liu L, Swanson M. Improving patient outcomes: role of the primary care optometrist in the early diagnosis and management of age-related macular degeneration. *Clinical optometry*. 2013 Feb 19:1-2.
11. Krishnakumar R, Anuradha N, Hussaindeen MJ, Sailaja MV. Role of optometrist in eye hospitals. *Medical & Vision Research Foundations*. 2016 Feb;34(1).
12. Sloan FA, Brown DS, Carlisle ES, Picone GA, Lee PP. Monitoring visual status: why patients do or do not comply with practice guidelines. *Health services research*. 2004 Oct;39(5):1429-48.
13. Musa M, Suleman A, Okechukwu C, Bale BI, Gagliano C, D'Esposito F, Zeppieri M. Diagnostic methods for managing dry eyes. *World Journal of Methodology*. 2025 Dec 20;15(4):101033.
14. Rosenfield M, Logan N. *Optometry: science, techniques and clinical management*. Elsevier Health Sciences; 2009 Jun 22.
15. Atchison EA, Omar AF, Iezzi R, Barkmeier AJ, Bakri SJ. Outcomes of an intravitreal injection clinic. *Retina*. 2017 Jul 1;37(7):1371-6.